Search

Methicillin-resistant Staphylococcus aureus (MRSA) carrying mecC gene (mecC-MRSA) is frequently reported among European hedgehogs (Europeaus erineaus) due to co-evolutionary adaptation to dermatophyte infection in European hedgehogs. The occurrence of MRSA in European hedgehogs in Finland is unknown. Consequently, we investigated the occurrence of MRSA in wild hedgehogs from urban Helsinki metropolitan area in 2020–2021 and applied whole genome sequencing (WGS) to further characterize the studied isolates and compared them with human clinical MRSA isolates. Altogether 115 dead hedgehogs were screened for MRSA using selective cultivation methods. Presumptive MRSA isolates were tested for antimicrobial susceptibility and confirmed MRSA isolates were further characterized by spa-typing and WGS. Hedgehog derived MRSA isolates were compared with clinical human MRSA isolates using core genome multilocus sequence typing (cgMLST). In total MRSA was recovered from 11 out of 115 (10%) hedgehogs. Among these four different spa types (t304; n = 4, t8835; n = 4, t5133; n = 2 and t622; n = 1) and three different sequence types (STs) (ST6; n = 6, ST7663; n = 4 and ST2840; n = 1) were identified. From the studied MRSA isolates seven harboured the mecA gene (mecA-MRSA) and four were identified as mecC-MRSA. All mecA-MRSA isolates carried immune evasion cluster genes, and one isolate was positive for Panton-Valentine leukocidin. cgMLST comparison revealed close genetic relatedness among three hedgehog and two human mecA-MRSA isolates all belonging to t304/ST6. Our results suggest a clonal dissemination of a successful MRSA clone among humans and hedgehogs. Further studies are warranted to investigate the sources and dissemination of such clone in urban environments. We observed a relatively low occurrence of mecC-MRSA in Finnish hedgehogs.

Background:Despite concerns that antimicrobial treatment of prevalent infections may select for drug-resistant bacteria, the effects of antimicrobial treatment on colonization dynamics have not been well quantified. Methods:We measured impacts of antimicrobial treatment on nasopharyngeal carriage of penicillin-susceptible Streptococcus pneumoniae (PSSP) and penicillin-nonsusceptible (PNSP) lineages at the end of treatment and 15, 30, and 60 days after treatment in a previously conducted randomized, double-blinded, placebo-controlled trial of amoxicillin-clavulanate for stringently defined acute otitis media. Results:In intention-to-treat analyses, immediate treatment with amoxicillin-clavulanate reduced PSSP carriage prevalence by 88% (95% confidence interval [CI], 76%-96%) at the end of treatment and by 27% (-3%-49%) after 60 days but did not alter PNSP carriage prevalence. By the end of treatment, 7% of children who carried PSSP at enrollment remained colonized in the amoxicillin-clavulanate arm, compared with 61% of PSSP carriers who received placebo; impacts of amoxicillin-clavulanate persisted at least 60 days after treatment among children who carried PSSP at enrollment. Amoxicillin-clavulanate therapy reduced PSSP acquisition by >80% over 15 days. Among children who carried PNSP at enrollment, no impacts on carriage prevalence of S. pneumoniae, PSSP, or PNSP were evident at follow-up visits. Conclusions:Although the absolute risk of carrying PNSP was unaffected by treatment, antimicrobial therapy conferred a selective impact on colonizing pneumococci by accelerating clearance and delaying acquisition of PSSP.

Colistin resistance mediated by mobile mcr‐1 gene has raised concern during the last years. After steep increase in mcr‐1 reports, other mcr‐gene variants (mcr‐2 to mcr‐5) have been revealed as well. In 2016, a clinical study was conducted on asymptomatic stool carriage of extended spectrum beta‐lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae among Finnish adults. All suspected ESBL producing bacterial isolates were first tested by phenotypic ESBL‐confirmation methods, and then further analyzed with whole genome sequencing to identify the resistance genes. We found one study subject carrying a colistin resistant E. coli with a transferrable mcr‐1 gene. This multi‐drug resistant isolate, although initially suspected to be an ESBL producer, did not carry any ESBL genes, but was proven to carry several other resistance genes by using whole genome sequencing. Sequence type was ST93. The mcr‐1 gene was connected to IncX4 plasmid which suggests that the colistin resistance gene locates in the respective plasmid. Here, we report the finding of a mcr‐1 harboring human E. coli isolate from Finland. Clinical antimicrobial resistance (AMR) rates are low in Finland, and mobile colistin resistance has not been reported previously. This highlights the importance of AMR surveillance also in populations with low levels of resistance. [ABSTRACT FROM AUTHOR]

The article reports that since 1991, Enterococcus faecium have been listed as the second leading nosocomial pathogen and are among the five most common causative agents of bloodstream infections.The issue of the emergence of Enterococcus faecium as a significant clinical problem at an adult haematology ward is discussed.

Background: Methicillin-resistant staphylococci (MRS) are increasingly being isolated in bovine mastitis. The aim of our study was to evaluate the occurrence of MRS in Finnish mastitis milk samples and characterize the MRS isolates using molecular methods. Results: Methicillin-resistant S. aureus (MRSA) was a rare finding in bovine mastitis in Finland. Only two out of 135 (1.5%) S. aureus isolates were positive for mec genes. One of these carried mecA and was of spa type t172, SCCmec type IV and ST375, and the other harboured mecC, being spa type t3256, and ST130. MRSA ST375 is common among human MRSA isolates in Finland, but this is the first report in the country of bovine mecC MRSA. In coagulase-negative staphylococci (CoNS) originating from bovine mastitis, methicillin resistance was more common. In the two CoNS collections studied, 5.2% (17/324) and 1.8% (2/110) of the isolates were mecA positive. Eighteen of these were methicillin-resistant S. epidermidis (MRSE), which were divided into 6 separate PFGE clusters. One pulsotype was detected in different parts of the country, indicating clonal spread. Most MRSE (13/18) were of SCCmec type IV, one was of type V and four were non-typeable. Comparison with a human staphylococcal database indicated that bovine MRSE strains were not closely related to human MRSE isolates. Conclusions: The occurrence of MRS, especially MRSA, in bovine mastitis in Finland was low. Most methicillinresistant bovine CoNS are MRSE, and we found evidence of a bovine MRSE strain that may spread clonally. This is the first report of a Finnish bovine isolate of MRSAmecC ST130. The study provides a baseline for further MRS monitoring. [ABSTRACT FROM AUTHOR]

Microbiology reference laboratories perform a crucial role within public health systems. This role was especially evident during the COVID-19 pandemic. In this Viewpoint, we emphasise the importance of microbiology reference laboratories and highlight the types of digital data and expertise they provide, which benefit national and international public health. We also highlight the value of surveillance initiatives among collaborative international partners, who work together to share, analyse, and interpret data, and then disseminate their findings in a timely manner. Microbiology reference laboratories have substantial impact at regional, national, and international levels, and sustained support for these laboratories is essential for public health in both pandemic and non-pandemic times., Competing Interests: Declaration of interests EV has received research grants from the French Public Health Agency, Pfizer, and MSD (paid to Centre Hospitalier Intercommunal de Créteil). SD has received a research grant from Pfizer; and advisory board and speaker fees from Merck-MSD (paid to University Hospitals Leuven). MH and CC have received funding from the Federal Office of Public Health (paid to The Swiss National Reference Center for Invasive Pneumococci). MH has participated on a data safety monitoring board or advisory board for both Pfizer and MSD. MH also holds investigator-initiated grants from Pfizer and MSD paid to his institution. However, the sponsors had no role in the data analysis and content of this manuscript. AS and AKu have received funding from the National Science Centre, MSD, and Pfizer; and equipment from The Great Orchestra of Christmas Charity Foundation and the Clinical Microbiology Center Foundation (paid and sent to The National Medicines Institute, Warsaw). AKu has received payments from Sandoz, and Pfizer for lectures. AS has received payments from MSD and Pfizer for lectures; and from MSD, Pfizer, and Sanofi Pasteur for participation on advisory boards. LL and MT have received research funding from Pfizer (paid to The Finnish Institute for Health and Welfare). ABB has received funding from MSD for IRIS pneumococcal genome sequencing. ABB is an unpaid advisor to WHO, providing expertise related to vaccines and antimicrobial resistance. ABB is also an unpaid General Assembly member (from 2022 onwards); and was a board member from 2016 to 2022, and Secretary from 2018 to 2022 for the International Society of Pneumonia and Pneumococcal Diseases. MD has received financial support from Pfizer to attend national scientific meetings. HH has received a grant from Pfizer to investigate Irish pneumococcal serotypes with whole genome sequencing. HH has received consulting fees from Bons Secours Hospital Group (Ireland). HH has received payment from the Scottish Hospitals Enquiry for expert testimony. KAJ has received personal royalties from GSK; and personal honoraria from the Wellcome Trust. T-TL has received consulting fees from the Trond Mohn Foundation. T-TL is an unpaid board member for the European Society for Meningococcal and Haemophilus influenzae disease, and the German Society for Hygiene and Microbiology (committee for microbial systematics, population genetics and infection epidemiology). H-CS has received funding from Pfizer for a pneumococcal carriage project. H-CS has received funding for consultations on a data safety monitoring board or advisory board for MSD. MPGvdL has received research funding from Pfizer and Merck (paid to the Reference Laboratory for Streptococci in Aachen, Germany); has received consulting fees from Pfizer, Merck, and GSK; payment or honoraria from Pfizer and Merck; and support for attending meetings or travel from Pfizer. AvG is the chairperson for the National Immunization Technical Advisory Group (National Advisory Group on Immunization) for South Africa. NMvS has received fees for services and consulting fees from MSD and GSK; consulting fees from Pfizer; and research funding from the Dutch Health Counsel, Argenx, Leducq Foundation, and Amsterdam UMC (all paid to their institution). NMvS holds a patent (WO 2013/020090 A3) on vaccine development against Streptococcus pyogenes. NMvS is an unpaid scientific advisor to the ItsME foundation, and a scientific advisor to Rapua te me ngaro ka tau (fees are paid to the University of Amsterdam). NMvS holds personal stock in Genmab and the Bank of America. JY has received payments for lectures given at scientific meetings organised by MSD and Pfizer; has received support from MSD and Pfizer to attend national and international scientific meetings; and has participated on MSD and Pfizer advisory boards. JS has participated on advisory boards for MSD. HC has received payment from Sanofi-Aventis Germany for a lecture; and is an unpaid external advisor to the German Standing Committee on Vaccination. SM is an unpaid external expert for an advisory board for enquiry into the landscape for a MenB vaccine in South Africa. JVM performs contract work for the Institute of Health Carlos III funded by GSK and Pfizer; and receives consulting fees from Pfizer and Sanofi Pasteur. MC has received an Investigator Initiated Research grant from Pfizer (W1243730; paid to their institution, Children's Health Ireland). MC is part of a working group for The National Immunisation Advisory Committee in Ireland. KGK has received funding from the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) to attend the ESCMID global meeting in Barcelona as a member of the Professional Affairs Subcommittee. CM-A has received payments for invited lectures given at scientific meetings for MSD, Sanofi-Pasteur, and Pfizer. CM-A has received support from MSD and Pfizer to attend national and international scientific meetings. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)